Abbott Laboratories $(ABT)$ shares tumbled 5.12% in pre-market trading on Thursday, despite the company reporting second-quarter results that slightly exceeded analyst expectations. The healthcare giant posted adjusted earnings per share of $1.26, marginally above the $1.25 estimate, and revenue of $11.1 billion, surpassing the projected $11.07 billion.

However, investors appear to be focusing on Abbott's forward guidance and expansion plans. For the third quarter, the company expects adjusted earnings per share in the range of $1.28 to $1.32, while for the full year 2025, it projects adjusted EPS between $5.10 and $5.20. This outlook, while in line with or slightly above current estimates, may be viewed as conservative by some market participants.

Adding to the mix, Abbott announced plans to build a new manufacturing facility in the U.S. state of Georgia by 2028. While this move signals long-term growth intentions, it could potentially impact the company's expenses in the coming years. Furthermore, Abbott provided an outlook for fiscal year 2025 organic sales growth, excluding COVID-19 testing related sales, to be in the range of 7.5% to 8.0%, which may not have met the market's more optimistic expectations.